Infliximab is a chimeric humanised mouse anti-TNF monoclonal antibody, that binds to and inhibits human TNF-alpha.
It has been used in the treatment for acute Crohn's disease, but was primarily designed for the treatment of rheumatoid arthritis.
It is given by intravenous infusion at 0,2 and 6 weeks then every 8 weeks thereafter. It is licensed for concomitant use with Methotrexate in adults with RA responding inadequately to DMARDs including methotrexate.
Check the Summary of Product Characteristics before prescribing this drug.
Last reviewed 01/2018